Cube Biotech and IBA Lifesciences, two innovators in the biotechnology industry, have merged to create a unified entity dedicated to advancing research and production capabilities for the life science industry.

The combined company will leverage its complementary strengths to deliver solutions in protein purification and stabilization and to enable research in the field of challenging drug targets.

By combining Cube Biotech’s expertise in protein technologies with IBA Lifesciences strength in high-performance research tools for protein isolation and analysis, the new entity aims to address the evolving needs of researchers and industry professionals worldwide.

Didier Dargent, CEO of Cube Biotech, stated, “This acquisition marks an exciting new chapter for both companies. Together, we will harness our collective expertise to push the boundaries of what’s possible in the life sciences and enable researchers to make groundbreaking discoveries.”

Mike Rothe, CEO of IBA Lifesciences, added, “The fusion of our technologies and talents creates an outstanding foundation for innovation. Our combined efforts will benefit our customers and strengthen our position as leaders in the biotechnology market.”